Clinical Trial

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Study acronym: TOPAZ-UC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC). Study participation will last approximately 118 weeks, including 104 weeks of treatment and may include up to 21 visits.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2025-09-16; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2025-11-21
Trial Details
NCT Number NCT07186101
Lead Sponsor Eli Lilly and Company
Conditions Ulcerative Colitis
Enrollment 252 participants
Start Date 2025-11-10
Primary Completion 2027-05 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-06